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Theability toderiveawhole-genomemapof
transcription-factor binding sites (TFBS) is
crucial for elucidating gene regulatory net-
works. Herein, we describe a robust ap-
proach that couples chromatin immunopre-
cipitation (ChIP) with the paired-end ditag
(PET) sequencing strategy for unbiased and
precise global localization of TFBS. We
have applied this strategy to map p53 tar-
gets in the human genome. From a satu-
rated sampling of over half amillion PET se-
quences, we characterized 65,572 unique
p53 ChIP DNA fragments and established
overlapping PET clusters as a readout to
define p53 binding loci with remarkable
specificity. Based on this information, we
refined the consensus p53 binding motif,
identified at least 542 binding loci with
high confidence, discovered 98 previously
unidentified p53 target genes that were im-
plicated in novel aspects of p53 functions,
and showed their clinical relevance to p53-
dependent tumorigenesis in primary cancer
samples.
INTRODUCTION
The recent completion of human genome sequencing (Inter-
national Human Genome Sequencing Consortium, 2004)
marked a major milestone in modern biology. The focus
now has turned to the annotation of genomes for functional
content, including gene-coding units and cis-acting regula-tory elements that modulate gene expression (ENCODE Pro-
jectConsortium, 2004). Gene expression in eukaryotic cells is
controlled by regulatory elements that recruit transcription
factors with specific DNA recognition properties. Thus, the
identification of functional elements suchas transcription-fac-
tor binding sites (TFBS) on a whole-genome level is the next
challenge for genome sciences and gene-regulation studies.
Chromatin immunoprecipitation (ChIP) is a powerful tech-
nique for analyzing TFBS in living cells. The technology most
commonly employed to map TFBS in a high-throughput
manner is ChIP-on-CHIP. This strategy has been success-
fully applied for whole-genome localization analysis of
TFBS in yeast (Ren et al., 2000). However, it has not been
readily applicable for comprehensive survey of TFBS in hu-
man and other mammals due to the large size and complex-
ity of these genomes. Recently, substantial progress has
been reported (Kim et al., 2005b), in which high-density-tiling
oligo arrays that cover 25% of the sequenced human ge-
nome were used to map active promoters. Nevertheless,
ChIP-on-CHIP technology for mammalian systems has
been developed on a limited scale. Most applications are
so far restricted to promoter microarrays containing CpG is-
lands or flanking sequences around transcription start sites
and specific chromosome arrays (Horak et al., 2002; Wein-
mann et al., 2002; Cawley et al., 2004; Boyer et al., 2005).
Despite considerable success, these partial genomic arrays
have provided limited information.
Alternatively, immunoprecipitated DNA fragments from
ChIP experiments can be cloned and sequenced (Wein-
mann et al., 2001; Hug et al., 2004). Although ChIP can en-
rich for TFBS-containing DNA fragments, a significant
amount of background DNA will still be present in the immu-
noprecipitated DNA material. With a limited survey of the
cloned ChIP DNA fragment pool, it is difficult to distinguish
between genuine binding sites and noise without further mo-
lecular validation. However, with a larger sampling of the
DNA pool, the sequencing-based approach has the poten-
tial to identify the DNA segments enriched by ChIP. The lim-
itation of standard sequencing is the time and cost ofCell 124, 207–219, January 13, 2006 ª2006 Elsevier Inc. 207
sequencing to achieve information saturation. The depth of
coverage can be enhanced by alternative sequencing strat-
egies such as serial analysis of gene expression (SAGE),
which was originally developed for counting transcripts and
was also recently applied to genome scanning for TFBS
and histone modification (Impey et al., 2004; Kim et al.,
2005a; Chen and Sadowski, 2005; Roh et al., 2005). Yet
this monotagging approach suffers from the inherent ambi-
guity of mapping short monotags to the genome and the in-
ability to distinguish true ChIP enrichment from amplified
noise generated during molecular cloning.
To exploit the efficiency of sequencing short tags, to in-
crease the information content, and to enhance the accu-
racy in mapping to the genome, we have developed a
paired-end ditag (PET) method that extracts 36 bp signa-
tures with 18 bp from the 50 end and another 18 bp from
the 30 end of each cDNA clone, concatenates the PETs for
efficient sequencing, and maps the PET sequences to the
genome to demarcate gene-transcription boundaries (Ng
et al., 2005). Conceptually, this strategy has the advantage
over SAGE of higher information content, permitting the de-
finitive mapping of the majority of tags to the genome, and is
at least 30-fold more efficient than standard cloning and se-
quencing approaches. To develop and validate this strategy
for applications in ChIP (which we now call ChIP-PET), we
chose the p53 tumor suppressor, a sequence-specific
DNA binding transcription factor.
As a transcription factor, p53 regulates the expression of
genes involved in a variety of cellular functions, including
cell-cycle arrest, DNA repair, and apoptosis (Vogelstein
et al., 2000). In the past decade, numerous efforts have
been made to identify p53-targeted genes through various
gene-expression techniques, including microarray and
SAGE combined with bioinformatics tools (Yu et al., 1999;
Zhao et al., 2000; Kannan et al., 2001; Kho et al., 2004). To
date, a large number of p53-responsive genes have been
identified, mostly based on gene-expression data, yet only
a small subset of these genes had direct binding evidence
(el-Deiry et al., 1992; Yoon et al., 2002; Yin et al., 2003;
Chen and Sadowski, 2005). Individual ChIP assay has been
applied to validate p53 direct targets (Mirza et al., 2003) but
is highly inefficient for identifying p53 targets on a global
scale. Recently, the ChIP-on-CHIP approach was used to
identify p53binding sites in chromosomes 21 and 22 (Cawley
et al., 2004). However, this experiment represented only 2%
of the human genome and therefore provided only limited
coverage for p53 binding. Herein, we describe the whole-
genome localization of p53 TFBS, show the effectiveness
of ChIP-PET for the identification of novel p53 target genes,
and demonstrate the clinical relevance of a subset of these
genes in tumorigenesis in vivo.
RESULTS
Mapping of p53 ChIP DNA Fragments
by Paired-End diTags
The underlying concept of ChIP-PET analysis is to clone the
immunoprecipitated chromatin fragments into a DNA library208 Cell 124, 207–219, January 13, 2006 ª2006 Elsevier Inc.that captures the original representation of ChIP DNA frag-
ments. The clones of the library are then converted into
paired-end ditags that are concatenated and cloned as the
final ChIP-PET library for sequencing analysis (10–15 PETs
per sequence read). The PET sequences are then mapped
to the genome to define the boundaries of the cloned ChIP
fragments. We expect that the PETs derived from nonspe-
cific fragments will be randomly distributed along the ge-
nome as background (PET singletons), while the PETs orig-
inating from the same locus containing the target binding site
will overlap with each other in a PET cluster whenmapped to
the genome (Figure 1; see also Figure S1 in the Supplemen-
tal Data available with this article online).
With this efficient and specific readout, we characterized
the p53 ChIP fragments generated from human HCT116
colorectal cancer cells treated with 5-fluorouracil (5-FU) for
6 hr, a condition known to activate p53 expression and tran-
scription of its downstream targets (Kho et al., 2004). From
approximately 40,000 sequencing reads, we produced
512,876 PET sequences, of which 75% (382,741) were
mapped to single locations in the human genome. The rest
of the PETs were either mapped to multiple locations, as
they might derive from repetitive sequences, or were not
mapped at all to the genome. These 382,741 PETs were fur-
ther grouped as distinct PETs (Figure S2), representing
65,572 PET-identified ChIP DNA fragments ranging from
100–4,000 bp with an average length of 624 bp. Since the
probability of generating identical DNA fragments by sonica-
tion during the ChIP procedure is assumed to be extremely
rare, the original ChIP DNA fragments prior to cloning are
most likely distinct from each other. Therefore, the redun-
dant PETs were regarded as copies amplified from the orig-
inal ChIP fragments during the cloning process, and the non-
redundant distinct PETs were considered to represent the
original ChIP DNA fragments. Based on the degree of PET
redundancy, we estimated the total number of identifiable
PET fragments in the original CHIP DNA material to be
82,659 by the Hill function (Kuznetsov, 2005) (Supplemental
Data I-6). Therefore, by extrapolation, the 65,572 distinct
PETs cover 80% of the entire ChIP DNA-fragment pool
captured in this library (Figure S3).
While the majority (61,270) of the distinct PET fragments
were located in the genome discretely (classified as PET sin-
gletons), 4,302 (7%) PETs were found overlapping with
others and were grouped into 1,766 PET clusters (Table 1).
These PET-cluster-defined genomic loci represent potential
p53 interaction sites in the genome. To assess the probabil-
ity that PET overlapping was due to random chance, we per-
formed a Monte Carlo simulation (Supplemental Data I-6).
We estimated that 27% of the PET clusters with two overlap-
ping members (hereafter referred to as PET-2 for PET clus-
ters with two overlapping members, PET-3 for clusters
with three overlapping members, and so forth), 2.3% of the
PET-3 clusters, and 0.001% of the PET-4 clusters could re-
sult from random sampling (Table 1). This suggested that
about 73% of PET-2 clusters and over 97% of the PET clus-
ters with three or more overlapping members (PET-3+ clus-
ters) most likely represent the real ChIP enrichment events.
Figure 1. Schematic View of ChIP-PET
Analysis
TheChIPDNA fragmentswere cloned into a plas-
mid vector. Plasmids were then converted into
PETs for concatenation, cloning, and sequenc-
ing. The PET sequences were mapped to ge-
nome to demarcate the boundaries of DNA
fragments. PET singletons were considered
background, while overlapping PETs (PET clus-
ters) were regarded as enrichment by the same
immunoprecipitation events. The overlapping re-
gions (PET overlap) in a PET cluster may, there-
fore, contain TFBS.Furthermore, based on the frequency distribution of PET
clusters by size (number of members in each PET cluster),
we were able to establish a true PET-cluster curve that is dis-
tinctive from the potential noise curve and estimate the level
of nonspecific PET clustering events (Supplemental Data
I-6). By extrapolating the true PET-cluster curve, we pro-jected that less than 36% (520 of 1443) of the PET-2 clusters
but over 99% of the PET-3+ clusters might represent true
enrichment by p53 ChIP (Table 1; Figure S4). Thus, using
two statistical analyses, one based on simulation of random-
ness and the other based on the data-distribution curve, we
concluded that PET singletons were most likely background,Table 1. Enrichment of p53 Binding Loci by PET Clusters
PET Mapping and Statistic Estimation
Total PETs
PET
Singletons
PET Clusters
PET-3+
ClustersPET-2 PET-3 PET-4 PET-5 PET-6 PET-7 PET-8+
Distinct PETs 65,572 61,270 2,886 471 252 175 168 91 259 1,416
Monte Carlo
simulation
65,572 64,790 770.9 11.1 0.0034 <0.0001 <0.00001 <0.00001 <0.00001
Random
probability (%)
27 2.3 <0.001 <0.0001 <0.0001 <0.0001 <0.0001
PET-defined loci 61,270 1,443 157 63 35 28 13 27 323
Goodness-of-fitting
analysis
3,742 520 159 69 38 22 14 33 335
Enrichment of p53 Binding Motifs in PET Clusters
Genome
Background
PET
Singletons
PET Clusters
PET-3+
ClustersPET-2 PET-3 PET-4 PET-5 PET-6 PET-7 PET-8+
PET-defined loci 63,036a 61,270 1,443 157 63 35 28 13 27 323
p53PET prediction 430 968 219 96 53 25 26 11 24 235
p53PET prediction % 0.68 1.58 15.18 61.15 84.13 71.43 92.86 84.62 88.89 72.76
p53MH prediction 1,117 1,541 196 69 45 23 21 11 21 190
p53MH prediction % 1.77 2.51 13.5 43.95 71.43 65.71 75 84.62 77.78 58.82
The random probability of PET overlapping was calculated based on the simulated numbers versus the observed numbers in each
category of PET clusters.
a The same number (61,270 + 1,766 = 63,036) and sizes (average 630 bp) of genomic DNA segments as the PET-defined loci were ran-
domly extracted from the human genome assembly (hg17) as background.Cell 124, 207–219, January 13, 2006 ª2006 Elsevier Inc. 209
the PET-2 clusters were enriched for p53 ChIP DNA frag-
ments but included substantial noise, and the PET-3+ clus-
ters were highly specific for p53 ChIP enrichment.
Verification of PET-Cluster-Identified
p53 Binding Loci
To verify whether the genomic loci determined by PET clus-
ters are associated with p53 interactions, we examined a list
of 66 known p53-responsive genes for the localization of
PET clusters (±100 kb around each curated gene in the
human genome). These genes had been demonstrated to
be activated by genotoxic treatment in HCT116 cells (Kho
et al., 2004) or are well-known p53 targets (Polyak et al.,
1997; Vogelstein et al., 2000). It is expected that some of
these genes would be directly targeted by p53 binding
and some secondary effectors. Forty-one of these sixty-six
genes were localized by PET clusters, including twenty-three
genes by PET-3+ clusters, eighteen by PET-2 clusters (Table
S2), and three by multiple PET clusters. For instance,
CDKN1A is a well-characterized p53 target gene encoding a
cyclin-dependent kinase inhibitor (Kaeser and Iggo, 2002)
with a confirmed p53 binding site in its promoter region.
We found a PET-13 cluster within the first 2,600 bp of the
promoter region, identifying 97 bp of overlap that coincided
with the previously characterized p53 binding site (el-Deiry
et al., 1993) (Figure 2A). Unexpectedly, we also found
a PET-5 cluster located 11,447 bp further upstream of the
CDKN1A transcription start site. The overlapping segment
(153 bp) in the PET-5 cluster also contained a recognizable
p53 binding motif. To specifically validate the localization
of PET clusters in the 50 region of CDKN1A, we scanned
the entire 12,000 bp genomic span using the conventional
ChIP quantitative PCR (ChIP-qPCR) assay. As illustrated in
Figure 2B, both of the p53 binding loci were confirmed,
and the genomic segments showing peak ChIP enrichment
were superimposable on the PET overlapping regions (Fig-
ures 2A and 2B). More examples of PET clusters mapped
to known p53 targets are shown in Figures S5 and S6.
The remaining 25 genes in this list either were not hit by
any PETs or were hit only by PET singletons. Hence, over
62% (41 of 66) of known p53-responsive genes in this list
were localized by PET clusters. This high matching rate of
PET clusters to known p53-responsive genes is statistically
significant (p value = 9e14), suggesting that genomic loci
determined by PET clusters are substantially enriched with
reliable p53 binding sites. Furthermore, 16 out of the 25
p53-responsive genes not associated with PET clusters
had no binding data in previous studies, suggesting that
these genes are not p53 direct targets but secondary effec-
tors in p53 regulation pathways. For the nine genes that had
previous binding data but were missed by PET clusters, we
conducted ChIP-qPCR assay for the previously known bind-
ing regions and found that the binding loci of three genes
were significantly enriched by p53 ChIP, including one
gene (TRAF4) hit by a PET singleton covering an authentic
p53 consensus motif. The other six were marginally enriched
andnot statistically significant above background (Figure S7),
including PIG3 and p53AIP1, known for their low binding210 Cell 124, 207–219, January 13, 2006 ª2006 Elsevier Inc.affinity for p53 protein (Kaeser and Iggo, 2002), and were
therefore not easily detected by PET sequencing or other
measurement. These results indicate that more than 93%
(41 of 44) of p53 targets enriched by ChIP procedure in
this study were identified.
For further validation, we randomly selected 40 genomic
loci defined by PET-3+ clusters as target segments for
ChIP-qPCR assay. All 40 loci (100%) showed significant en-
richment (Figure 2C), indicating that these regions are true
p53 binding targets.
Together, based on the high percentage of PET-cluster
hits to known p53 targets, the precise localization of many
previously known p53 binding sites by PET overlapping re-
gions, and the 100% confirmation by ChIP-qPCR assays
of the 40 binding loci identified by PET clusters, we have
convincingly established the use of PET clusters as an effi-
cient and accurate readout for identifying p53 binding loci.
We therefore believe with high confidence that the 323 geno-
mic loci determined by PET-3+ clusters in this study em-
brace true p53 protein binding sites.
Characterization of the p53 Binding Motif
Using the PET-Cluster-Defined Loci
The currently known p53 binding motif is loosely defined
(el-Deiry et al., 1992). Although the degenerate nature of
the p53 DNA binding element may reflect the diversity and
flexibility of p53-mediated responses to numerous cellular
stress signals, this degeneracy complicates the detection
and prediction of p53 binding sites in the whole genome.
The genome-wide identification of p53 binding loci as rep-
resented by the large number of PET clusters in this study
provided an unprecedented opportunity for delving deeper
into the nature of DNA binding by p53. To ask whether
a key motif (or motifs) existed among the PET clusters, we
first randomly picked 39 binding loci as the initial seed set
for motif discovery followed by program training from the
68 PET-6+ cluster sequences. After applying a de novo
motif-discovery algorithm, GLAM (Frith et al., 2004), a single
prominent motif was identified, which undisputedly resem-
bled the known consensus of p53 binding sites (Supplemen-
tal Data I-7). After further expectation-maximization-type op-
timization employing ROVER (Haverty et al., 2004), we
established a highly effective model (hereafter referred to
as the p53PET model) (Figure 3A). The effectiveness of the
p53PETmodel for prediction of p53 binding sites was tested
using the remaining 284 binding loci localized by PET-3+
clusters, and the performance of p53PET was evaluated in
comparison with the previously reported p53MHmodel (Hoh
et al., 2002) and the p53PET model with its weight matrix
replaced by the one in the TRANSFAC database (Wingender
et al., 2000). As shown in Figure 3B using receiver operating
characteristic (ROC) curves, it is evident that the p53PET
model achieved much higher sensitivity for detecting p53
binding motifs than the other two models at all specificity
levels. More importantly, the lengths of the spacers between
the two half-sites in these 284 motif sequences are predom-
inantly zero, although a few are 1 bp, and longer spacers
are also observed (Figure 3C). This length distribution
Figure 2. Validation of PET-Cluster-Identified p53 Binding Loci
(A) The whole-chromosome view of p53 ChIP-PETsmapping to chr6. A genomic span of 23 kb that contains theCDKN1A gene and its 50 region is enlarged.
CDKN1A was localized by two PET clusters; one contained 5 PETs, and the other contained 13 PETs. The two PET overlaps were 153 bp and 97 bp and
were located in chr6:36742675–36743642 and chr6:36751902–36754502, respectively. Both PET overlaps contained recognizable p53 binding motifs.
(B) ChIP-qPCR validation in the 50 upstream region of CDKN1A.
(C) p53 ChIP DNA (blue) and control GST ChIP DNA (red) were subjected to ChIP-qPCR analyses to determine the relative enrichment of candidate regions
identified by ChIP clusters.is much more specific than reported in previous studies,
where spacers were simply said to vary between 0 and
14 bp.Using the p53PET prediction model, we then analyzed all
PET-localized regions for p53 motif finding. As summarized
in Table 1, the percentages of the predicted p53 bindingCell 124, 207–219, January 13, 2006 ª2006 Elsevier Inc. 211
Figure 3. Motif Analysis of p53 Binding
Sites
(A) Sequence logos depicting nucleotide distribu-
tions for the two p53 half-sites based on the
p53PET model.
(B) ROC curve comparison between p53PET,
p53TRANSFAC, and p53MH.
(C) The spacer lengths between the two halves of
p53 binding motifs in PET-3+ clusters.motifs were very low (0.68%) in the randomly selected geno-
mic segments taken to represent background noise and
similarly low (1.58%) in the PET singletons, reiterating the
fact that most of the PET singletons are experimental noise,
but significantly higher in PET clusters. We also observed a
sharp increase in the p53 motif-containing rate, from
15.18% in PET-2 clusters to 61.15% in PET-3 clusters, and
the escalation continued. This is consistent with our early es-
timates by statistical analysis that, although PET-2 clusters
are enriched for p53 response elements, they also contain
substantial noise, while the PET-3+ clusters are highly reli-
able. Overall, 73% of the PET-3+ clusters possessed recog-
nizable p53 binding sites, which is a significant enrichment
(up to 107-fold) as compared to background, suggesting
again that the specific p53 interaction with the genome is
predominantly through direct binding to a single binding212 Cell 124, 207–219, January 13, 2006 ª2006 Elsevier Inc.motif. We suspect that the 27% non-motif-containing bind-
ing loci identified by PET-3+ clusters might be due to recruit-
ment of p53 to genomic locations through indirect DNA
binding as has been found for the estrogen receptor (Carroll
et al., 2005). Again, compared with p53MH, the p53PET
model showed better prediction results for p53 motif finding,
with greater distinction between background and high-prob-
ability PET clusters (i.e., fewer hits in the background set of
random genomic DNA segments and PET singletons and
greater detection in PET-cluster sequences) (Table 1). De-
spite the relative nonspecificity of PET-2 clusters, using the
new p53PET motif-finding model, we were able to identify
219 PET-2 clusters with high likelihood of p53 interaction re-
gions containing p53 binding motifs. Thus, including the 323
binding loci identified by PET-3+ clusters, we have estab-
lished a total of 542 high-probability p53 binding loci.
While our total number (1,766) of PET clusters is in good
agreement with the 1,600 binding sites as extrapolated
from the p53 localization analysis for chromosomes 21 and
22 using ChIP-on-CHIP (Cawley et al., 2004), the specific
binding sites on these chromosomes had significant non-
overlap between the two experiments. In the two chromo-
somes, 48 loci based on hybridization peaks were identified,
while in this study we had 55 PET clusters. Within these PET
clusters, 5 were PET-3+ clusters (3 of them contain the p53
motif), and 8 were PET-2 clusters that contain idealized
p53bindingmotifs (Table S3). By our earlier validation results,
these 13 loci identified by PET clusters (11 containing p53
motifs) were considered high confidence with regards to
p53 binding, including one that wasmapped in the first intron
of a known p53-responsive gene (PRODH/PIG6) (Polyak
et al., 1997). Three of the thirteen PET-cluster-determined
loci were also identified by the p53 ChIP-on-CHIP analysis.
One of the common loci was in a gene desert region with
the nearest gene model (C21orf116) 112 kb away from its
50 side, one was localized in an internal intron region of
SMARCB1, and the other was in the first intron of
AB051436. We further applied our optimized p53PET motif-
findingmodel to the 48 loci derived fromChIP-on-CHIP anal-
ysis and found that only 5 of them had the requisite p53
binding motif. We observed that the PET-derived loci were
significantly more likely to contain a p53 motif (11 of 13, or
85%) than loci identified by ChIP-on-CHIP (5 of 48, or
10%). The most interesting discrepancy in this group is the
binding locus localized by a PET-8 cluster on chromosome
21 (chr21:33660665–33662530) but missed in the ChIP-
on-CHIP study. This locus is 6,672 bp downstream of the
30 side of IFNAR1, which is involved in stress response to viral
infection. OurChIP-qPCRanalysis indeed confirmed that this
locus is a genuine in vivo binding site for p53 under 5-FU in-
duction conditions in HCT116 cells. Similarly, the binding
locus on chromosome 22 (chr22:27702966–27705354) lo-
calized by a PET-5 cluster was also validated. The discrep-
ancy between the two studies could be attributed to different
chemical treatments (5-FU versus bleomycin) and possibly
different stringencies used for determining binding loci.
Using the optimized p53PET motif-finding model, we
scanned the entire human genome and identified 13,885
ab initio p53 binding sites. Although with increased strin-
gency the p53 binding sites predicted by p53PET could be
reduced to a few thousand, the number is still significantly
larger than that experimentally identified. Besides a certain
level of false positives, it is possible that the predicted p53
binding sites represent the total capacity of p53 targeting
in the genome, while the experimentally identified loci in
each study may reflect only a subset of functional p53 sites
in that particular biological condition in a specific cell line.
Identification of Novel p53 Target Genes
Having established that the PET-cluster loci were highly as-
sociated with p53 interactions, the 542 loci determined by
a combined PET-clustering and motif analysis represent
a rich resource for the identification of novel p53 target
genes. Based on their location within 100 kb of transcriptionunits, we assigned 474 such clusters to 458 known genes
(Table S4). One hundred and fifty-six of the clusters were
50 upstream, forty-six were in the first introns, one hundred
and fifty-two were in internal introns, and one hundred and
twenty were in 30 downstream regions of the genes (Fig-
ure 4A). Significantly, none were found in exonic regions
(p value = 7e10, Supplemental Data I-6). Over 90% of the
binding sites were within 60 kb of the target genes, with
the highest density of binding sites (338 of 474; 71%) located
within approximately 20 kb of the 50 and 30 flanking regions.
To validate and further characterize these candidates for
p53 direct target genes, we obtained gene-expression
data for the same cell line (HCT116) treated under the
same condition (5-FU for 6 hr) using oligonucleotide microar-
rays containing 20,000 gene probes (Kho et al., 2004). Out of
the 458 PET-cluster-associated genes, 275 have corre-
sponding expression data, in which 65 were upregulated
and 57 downregulated in response to 5-FU in p53 wild-
type (+/+) versus p53 mutant (/) cells. We therefore con-
sider these 122 genes, characterized by both PET binding
data and expression data, as direct p53 target genes (Table
2). We asked whether upregulated genes had different bind-
ing characteristics from downregulated genes and observed
that a statistically significant proportion of upregulated genes
have their binding loci at 50 proximity and first introns (38 of
65 upregulated genes, p = 7.4e5; Supplemental Data I-6).
This suggests a potential difference between genes upregu-
lated and genes downregulated by p53 based on binding-
site location (Figure 4A).
The 122 direct targets identified by p53 binding compiled
in Table 2 include 24 known p53-responsive genes, while
the other 98 were not previously associated with p53 re-
sponse. Functional categorization of these genes revealed
a broad spectrum of p53 functions, including cell motility
and migration and receptor-tyrosine-kinase signaling cas-
cades (RTK/PTPase), in addition to well-characterized p53
functions. Strikingly, 20 novel p53 target-gene candidates
are associated with the regulation of cell motility and adhe-
sion. p53 has been implicated in regulation of tumor invasion
andmetastasis (Singh et al., 2002). However, it was not clear
which p53 target genes were involved in this cellular pro-
cess. To explore the possibility that p53 regulates metastasis
through transcriptional regulation of cell adhesion and motil-
ity genes, 18 targets in this category were selected to mea-
sure their expression levels in 5-FU-treated cells using real-
time qPCR. Of the tested genes, 15 were indeed modulated
(7 were up- and 8 were downregulated) by p53 activation,
and 3 were not affected. PCDH7 and VIM, which are in-
volved in cell adhesion and cytoskeleton structure, were
both downregulated, whereas ITGAM and Col4A1 were up-
regulated (Figure 4B). Our results point to the possibility that
p53 can suppress metastasis through direct transcriptional
regulation of a new category of molecular targets.
Clinical Relevance of p53 Direct Targets in Primary
Cancer Tissues
It is known that transcriptional regulation in cultured cells
might reflect in vitro artifacts, and tissue-dependent p53Cell 124, 207–219, January 13, 2006 ª2006 Elsevier Inc. 213
Figure 4. Location of p53 Binding Loci around Target Genes and Validation by Gene Expression
(A) Four hundred and seventy-four PET clusters were plotted against PET counts of each PET cluster (y axis) and locations (x axis) of corresponding genes
represented by a gene model based on BAX. Locations in 50 and 30 regions are indicated in kilobases, while locations in introns were plotted in proportion to
the gene length of that intron. The gray dots indicate PET clusters mapped to genes that either did not have expression data or showed no change in ex-
pression levels.
(B) Four novel p53 target genes (PCDH7, VIM, Col4A1, and ITGAM) were validated using real-time PCR for expression in 5-FU-treated HCT116 cells. Fold
changes relative to time 0 at indicated time points are plotted with HCT116 as solid blue bars and HCT116 p53/ as hollow bars. The error bars represent
95% confidence intervals. The locations of PET clusters with respect to their corresponding genes and the motifs (red bars) identified by p53PET are shown.transcriptional activity has been previously described
(Coates et al., 2003). To further validate the genes identified
by ChIP-PET as bona fide p53 targets, and to determine the
extent of their response to p53 in primary tumors, we studied
their expression patterns in a collection of 251 primary breast
tumors profiled using the Affymetrix U133A and B microar-
rays (Miller et al., 2005). In this set of tumors, the p53
cDNA had been previously sequenced, leading to the iden-
tification of 58 p53 mutant tumors and 193 tumors with
p53 wild-types (Bergh et al., 1995). All except one of the
122 p53 direct target genes were represented by probes
on the Affymetrix array. Using expression data derived
from the 251 breast tumors for 65 p53-activated genes
and 56 p53-repressed genes, respectively, we performed
unsupervised hierarchical clustering, which resulted in two
primary tumor clusters significantly associated with the p53
mutation status (Figures 5Aand5B). A number of p53-upreg-
ulated genes showed higher expression levels in most of the
p53 wild-type tumors relative to the p53 mutant tumors,
consistent with their transcriptional dependence on p53.
Similarly, a number of p53-downregulated genes were ex-
pressed at lower levels in the p53 wild-type tumors relative
to the mutants, consistent with their transcriptional repres-
sion by p53. Furthermore, dysregulation of these target
genes (i.e., lower expression of p53-activated genes and
higher expression of p53-repressed genes) was, in each
case, significantly linked to the development of distant me-
tastasis within 5 years of diagnosis. Pathologically, tumors214 Cell 124, 207–219, January 13, 2006 ª2006 Elsevier Inc.associated with this dysregulation appeared to be more
aggressive as evidenced by their higher tumor grades and
the observation that patients with these tumors had a signif-
icantly lower probability of surviving their cancer (Figures 5C
and 5D). Interestingly, two of the p53-repressed genes
known for their antiapoptotic functions, BCL2A1 and
TNFAIP8, showed the highest correlations with both p53
mutation status and high tumor grades. Although p53 is
known to repress antiapoptotic genes, such asBCL2, to reg-
ulate apoptosis, to our knowledge this is the first report that
BCL2A1 and TNFAIP8 are transcriptionally silenced by p53.
The observation that their expression patterns in the breast
tumors correlate highly with p53 status and clinical behavior
(Figure 5B) suggests they may be powerful new biomarkers
for patient prognosis.
Taken together, these findings strongly argue that most of
the novel p53 direct target genes identified by PET clusters
are bona fide p53 direct targets, are regulated by p53 in
different cell types, and are functional in p53-mediated
tumorigenesis. Furthermore, their expression characteristics
in vivo can potentially be used as molecular gauges of tumor
aggressiveness and clinical outcome.
DISCUSSION
The ChIP-PET strategy demonstrated in this study repre-
sents a substantial advance in our ability to identify cis-regu-
latory elements, notably transcription-factor binding sites, on
Table 2. Categories of p53 Target Genes Identified by ChIP-PET Analysis
Apoptosis
Cell Cycle
DNA
Repair
Chr.
Modifier
Cell Growth
Differentiation
Transcription
Regulation
Protein
Catabolism
Signal
Transduction
Cell
Adhesion
Mobility
Biosynthesis
Metabolism
Transport
and Ion
Channel Unknown
BAX PCNA IER5 ATF3 TRIM22 RRAD GPC3 RPS27L STAU FLJ11259
GADD45A RRM2B TGFA MYBL1 CPN1 SNX5 S100A2 TPO STARD4 WIG1
CCNG2 TP53AP1 BCAS3 ADORA2B NEDD4L DKK3 ANK1 ASTN2 EEA1 AB011136
CDKN1A XPC C2orf29 ADRB1 USP34 EIF2AK3 ARHGAP5 CHST12 KCNMA1 AK055226
GML CHD2 FGF2 CBLC USP9X ERBB4 BICD2 CYP4F3 OSBP ANKRD10
PIG6 DDB2 GSPT1 GNAQ GNAI1 CALD1 FTHFSDC1 SLC4A10 ANP32D
SNK HDAC9 KITLG GPR39 NCK2 CDC42EP3 LOC144501 TRPM1 B1
TNFRSF10B MLH1 MDM4 NAB1 NMU COL4A1 NAV3 BC004942
BCL2A1 MSH6 NR6A1 NOTCH1 CTNNA3 PCCA C2orf25
CNAP1 PCAF PPM2C FAT PRKAG2 CDKAL1
RBL1 PRDM1 PTPRE FLJ20972 DDIT4
SMARCB1 TIF1 PTPRM FRMD4A FLJ12484
TNFAIP8 UBP1 PTPRO ITGAM FLJ20045
LTBP1 FLJ22457
MYO1A HIG1
NEO1 LATS2
NID2 MDS009
NLGN1 PHF14
PCDH7 PIAS2
PPFIBP1 PSTPIP2
PTK2 ShrmL
VIM SPAG9
Previously known p53 targets are in italic; novel p53 targets are in roman.a whole-genome level. Unlike array-based approaches,
ChIP-PET is an open system for identifying any regulatory
binding loci that can be enriched by ChIP and requires only
standard sequencing capacity. The method is therefore
readily applicable for global localization analyses of TFBS in
any genome as long as the whole-genome sequence as-
sembly is available. ChIP-PET is also more precise for
TFBS mapping than the current approaches. We have dem-
onstrated that >80% of known and new p53 binding sites
identified in this study resided in the overlapping regions of
PET clusters, providing a way to narrow the TFBS down to
less than 100 bp. This is made possible by the unique feature
that characterizes the termini of individual PET-identified
fragments. As a result, we can unambiguously distinguish
the original ChIP DNA fragments (distinct PETs) from the am-
plified noise (redundant PETs with multiple copies) regard-
less of how much the amplification might be.
This feature of paired-end ditagging also sets the PET
strategy apart from the recently reported method using
SAGE-like monotags to map TFBS (Impey et al., 2004;Kim et al., 2005a; Chen and Sadowski, 2005; Roh et al.,
2005). In the monotag approach, each ChIP DNA fragment
is represented by a single tag of 20 bp, and tag counts
(copy number) are used to measure ChIP enrichment;
this approach cannot distinguish overlapped different ChIP
DNA fragments from redundant tags due to amplification
and therefore would significantly increase false positives as
we simulated with the data generated in this study (Fig-
ure S10). In contrast, the PET-cluster readout scheme is
more accurate in identifying binding loci and more specific
in narrowly defining binding sites.
Although the amount of sequencing required (40,000
sequencing reads) for a comprehensive ChIP-PET experi-
ment is miniscule for most sequencing centers and within
the reach of core facilities in university laboratories, the
cost for each ChIP-PET experiment is substantial. One ap-
proach to increase efficiency is to develop an effective sub-
traction scheme (Chen and Sadowski, 2005) to reduce the
level of background noise so as to decrease the number
of sequencing reads required. Ultimately, the ChIP-PETCell 124, 207–219, January 13, 2006 ª2006 Elsevier Inc. 215
Figure 5. In Vivo Analysis of p53 Target-Gene Expression
Unsupervised hierarchical cluster analysis of 251 breast tumors was performed using the 65 upregulated genes (A) or 56 downregulated genes (B) by p53 in
5-FU-treated HCT116 cells. The formation of two tumor clusters (C1 and C2) and the major tumor branch points are shown in the colored heat map. Red
indicates above-mean expression; green denotes below-mean levels. The degree of color saturation reflects the magnitude of expression value. Black ver-
tical bars represent p53 mutant tumors (p53 mt) or those that gave rise to a distant metastasis within 5 years of diagnosis (DM < 5 yr). Pale blue bars in the
rows of ‘‘p53 mt’’ and ‘‘DM < 5 yr’’ reflect missing data. Green and red bars reflect histological grade I and grade III tumors, respectively. Kaplan-Meier
disease-specific survival (DSS) plots are shown for the two major cluster branches formed in (A) (C) and (B) (D). p values were calculated by the chi-square
test.approach will be further empowered by new cost-effective
sequencing technologies under rapid development (Margu-
lies et al., 2005; Shendure et al., 2005). In particular, we have
adapted the multiplex sequencing method (Margulies et al.,
2005) for PET-based sequencing analysis to characterize216 Cell 124, 207–219, January 13, 2006 ª2006 Elsevier Inc.mammalian transcriptomes and interrogate complex ge-
nomes (P.N., J.J.S. Tan, K.P.C., H.S. Ooi, Y.L L., M.J. Full-
woods, L. Du, W.-K.S., C.-L.W., and Y.R., unpublished
data) and expect to reduce the sequencing cost to under
$5,000 per ChIP-PET experiment within a year.
After a saturated sampling, we scanned the entire human
genome for p53 TFBS under a given cellular condition,
established a comprehensive map of p53 binding, and
identified 542 loci with high confidence of p53 interaction.
This number is different from what was extrapolated (1,600)
from the p53 ChIP-on-CHIP analysis (Cawley et al., 2004),
and p53 loci on chromosome 21 and 22 localized by these
two different experiments shared minimal overlap. Compar-
ison between the two data sets is difficult because these two
chromosomes are poorly populated with well-characterized
p53 target genes, with the exception of PIG6/PRODH
(22q11.21), which was previously reported to be responsive
to p53 activation (Polyak et al., 1997). In our study, a PET-2
cluster was mapped to the first intron of this gene (Table S3)
and covered a p53 binding motif.
Given that p53 binding sites on chromosomes 21 and 22
identified by the ChIP-PET approach are significantly en-
riched for p53 binding motifs (85% versus 10%) as opposed
to sites assigned by ChIP-on-CHIP, it is likely that the ChIP-
PET methodology is more specific than ChIP-on-CHIP. In
addition, besides potential experimental variations and dif-
ferent techniques used in the two studies, one possible ex-
planation for such a discrepancy between the two results
is that, although the two experiments were done using the
same cells (HCT116), different induction treatments and
time points were employed (5-FU for 6 hr and bleomycin
for 12 hr). Time-course studies have shown clearly that the
binding of p53 to target sites is dynamic and changes signif-
icantly in the first 6 to 12 hr after any exposure to conditions
that induce DNA damage (Crosby et al., 2004). The differ-
ences between the effects of 5-FU and bleomycin could
also be substantial. 5-FU is a nucleoside analog and re-
places replicating nucleic acid with fluorinated uracil, result-
ing in wide-scale coding and structural alterations. Bleomy-
cin nicks DNA and introduces generalized strand breaks. In
fact, these two experiments maymerely represent two snap-
shots of potentially very large and fluid bodies of transcrip-
tional networks in response to different p53-activating sig-
nals. Thus, it is perhaps only through sampling of many
combinations of biological settings and p53-activating sig-
nals that we can obtain a truly comprehensive and complete
atlas of p53 genomic activity.
In addition to presenting a global view of p53 TFBS in the
human genome for the first time, this study also provided
a comprehensive list of p53 target genes and their responses
to p53 activation in colorectal cancer cells. Through crossva-
lidation in clinical breast tumors, we identified a comprehen-
sive panel of likely direct targets of p53, many of which ap-
pear to play a role in p53-dependent tumorigenesis in
primary cancer tissues. Functional analysis of these genes
revealed a broad spectrum of novel p53 functions, including
cell adhesion and migration and involvement in receptor-
tyrosine-kinase signaling cascades (RTK/PTPase). Recently,
p53 has been implicated in the regulation of tumor invasion
and metastasis (Tlsty, 1998). Our discovery of 20 previously
unidentified targets involved in cell motility, adhesion, and
migration suggests that a large number of novel p53 targets
could be involved in p53-mediated suppression of tumormetastasis. For example, PTK2 (known as focal adhesion
kinase, FAK) is known to promote cell invasion and metasta-
sis through integrin-mediated signaling (Lin et al., 2004) and
is overexpressed in invasive breast and colon cancers. It is
very likely that p53 suppresses metastasis through down-
regulation of PTK2. Furthermore, we identified VIM, the ex-
pression of which has been closely correlated with prostate
and breast cancer metastasis (Thompson et al., 1992; Singh
et al., 2002). The biological roles of these promising new
candidates in p53-regulated suppression of tumor migration
and metastasis warrant further investigation.
This study also raised new questions concerning p53 DNA
binding dynamics. Of the 542 high-confidence binding loci,
we have observed that many were either far away from prox-
imal promoter of genes or inactive in inducing adjacent gene
expression. Are these binding sites functional? If so, how do
they operate? It is possible that many of the p53 binding sites
function through long-distance interactions as enhancers or
locus control regions (LCRs) to modulate gene expressions
(West and Fraser, 2005), which can be investigated using
the 3C approach (Dekker et al., 2002). It is also possible
that a number of the p53 binding sites not associated with
array-detected transcriptional activity identified in this study
indicate that array probe analysis is blind to alterations in
splicing and alternative transcriptional start and end sites.
In addition, these sites might not permit recruitment of re-
quired cofactors to trigger transcriptional activity. p53 is
known to interact with coactivators or corepressors under
various conditions. For example, BNIP3L is a p53 binding
target, and its induction requires the simultaneous activation
of both p53 and hypoxia-inducible factor 1 (HIF-1) under
hypoxic conditions (Fei et al., 2004). The data generated in
this study potentially provide the initial framework for higher-
level interactions of p53 regulation.
In summary, we have developed an unbiased, highly pre-
cise, and efficient mapping methodology to allow the whole-
genome survey of TFBS with an unprecedented resolution.
The application of this approach to the discovery of p53
binding sites has enabled us to identify many new in vivo tar-
gets of the p53 tumor-suppressor protein. The characteriza-
tion of these targets by expression profiling in cultured can-
cer cells and primary tumors uncovered potentially important
pathological and clinical roles. Our findings expand the cur-
rent knowledge base surrounding p53 function and impli-
cate p53 in a greater diversity of biological activities than pre-
viously suspected.
EXPERIMENTAL PROCEDURES
Cell Culture and Drug Treatments
Human colon cancer cell line HCT116 and its derived isogenic p53/
cells (provided by Dr. Bert Vogelstein) were cultured in DMEM containing
10% FCS and treated with 5-fluorouracil and cycloheximide.
ChIP Experiment
ChIP assays with HCT116 cells were carried out as described (Weinmann
and Farnham, 2002;Wells and Farnham, 2002). For all ChIP experiments,
DO1 monoclonal antibody was used for immunoprecipitation, and quan-
titative PCR analyses were performed in real time using the ABI PRISMCell 124, 207–219, January 13, 2006 ª2006 Elsevier Inc. 217
7900 Sequence Detection System and SYBR Green Master Mix as de-
scribed (Ng et al., 2003). Relative occupancy values were calculated by
determining the apparent immunoprecipitation efficiency (ratios of the
amount of immunoprecipitated DNA over that of the input sample) and
normalized to the level observed at a control region, which was defined
as 1.0.
Construction of ChIP-PET Library
The end-polished ChIP DNA fragments were ligated to the cloning vector
pGIS3, which contains two MmeI recognition sites (Figure S1). The liga-
tions were transformed into TOP10 cells (Invitrogen) to form the ChIP
DNA library. Plasmid of the ChIP DNA library was digested with MmeI
and end polished with T4 DNA polymerase. The resulting vector contain-
ing a signature tag from each terminal of the ChIP DNA insert was self-
ligated and then transformed into TOP10 cells to form the ‘‘single-PET’’
library. The plasmids from this library were digested with BamHI to release
50 bp PETs, which were concatenated into long fragments (1–2 kb) and
cloned into pZErO-1 (Invitrogen) as the final ChIP-PET library for sequenc-
ing.
PET Extraction and Mapping to Genome
PET sequences were extracted from the raw sequence reads obtained
from the ChIP-PET library and were mapped to the human genome as-
sembly (hg17). The process of PET extraction and mapping is essentially
same as previously described for cDNA analysis (Ng et al., 2005).
Additional Methods
The Supplemental Data contain the above methods and additional
methods in more detail, statistical analyses, and p53 motif analyses.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, 11 figures, and 4 tables and can be found
with this article online at http://www.cell.com/cgi/content/full/124/1/
207/DC1/.
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